Hisilicon: Signs Exclusive Licensing Agreement with Nuvectis, Agreement includes additional milestone payments of up to $1.421 billion.

Haisi announced that the company has recently signed an exclusive licensing agreement with the US-based Nuvectis Pharma, Inc. to grant Nuvectis the exclusive rights to develop, manufacture, and commercialize the HSK42360 project globally outside of the Greater China region, as well as the exclusive rights to develop, manufacture, and commercialize the HSK39297 project globally outside of the Greater China, Southeast Asia, and India regions. As part of the consideration for the external licensing transaction, the company will receive licensing fees and sales royalties from Nuvectis for the HSK42360 and HSK39297 projects.